Accelerate Diagnostics Inc (AXDX) Receives $21.00 Average PT from Analysts
Accelerate Diagnostics Inc (NASDAQ:AXDX) has earned an average rating of “Hold” from the seven research firms that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $21.00.
AXDX has been the subject of a number of analyst reports. BidaskClub raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Wednesday, January 16th. Zacks Investment Research raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Friday, January 25th. Finally, Piper Jaffray Companies increased their price target on Accelerate Diagnostics to $22.00 and gave the company an “overweight” rating in a report on Wednesday, February 20th.
A number of large investors have recently added to or reduced their stakes in AXDX. Morgan Stanley lifted its holdings in Accelerate Diagnostics by 186.5% during the 1st quarter. Morgan Stanley now owns 476,232 shares of the medical research company’s stock worth $10,010,000 after buying an additional 310,031 shares during the last quarter. Cadian Capital Management LP bought a new position in Accelerate Diagnostics during the 1st quarter worth approximately $6,264,000. Amundi Pioneer Asset Management Inc. lifted its holdings in Accelerate Diagnostics by 33.0% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 991,090 shares of the medical research company’s stock worth $11,397,000 after buying an additional 246,000 shares during the last quarter. Raging Capital Management LLC bought a new position in Accelerate Diagnostics during the 4th quarter worth approximately $2,518,000. Finally, Griffin Asset Management Inc. lifted its holdings in Accelerate Diagnostics by 72.6% during the 4th quarter. Griffin Asset Management Inc. now owns 436,519 shares of the medical research company’s stock worth $5,020,000 after buying an additional 183,626 shares during the last quarter. 48.87% of the stock is currently owned by institutional investors.
Accelerate Diagnostics (NASDAQ:AXDX) last issued its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. The firm had revenue of $1.75 million during the quarter, compared to the consensus estimate of $2.12 million. Accelerate Diagnostics had a negative return on equity of 130.94% and a negative net margin of 1,352.80%. Research analysts expect that Accelerate Diagnostics will post -1.62 EPS for the current fiscal year.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.